InterMune, Inc.

An Almost Convincing Drug Castoff In 2006 I was almost convinced that the small biotech company Adherex Technologies, Inc. might do a better job with the drug eniluracil than GlaxoSmithKline plc (GS

I met the management of InterMune Inc. almost 20 years ago when it was a mid-sized US biotechnology company that had three approved products, two of them interferons. Virtually all of InterMune’s re

Chinese antiviral-focused venture Ascletis Pharma Inc. became the first biotech company to take advantage of revised and eased rules for the listing of pre-revenue/pre-profit ventures on the Hong Ko

Many years ago, around the time when the US FDA was considering a “reevaluation” of the erythropoiesis-stimulating agents (ESAs) with a forthcoming advisory committee, the agency's dean of drug develo